Predictive factors for a severe course of COVID‐19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival

Comment on “Predictive factors for a severe course of COVID‐19 infection in myasthenia gravis patients with an overall impact on myasthenic status and survival” by Jakubíková et al.

“…We read with interest the report by Jakubíková et al [1] on predictive factors affecting myasthenia gravis (MG) and survival in severe COVID‐19 patients at two centers in the Czech Republic.…”

“…Therefore, we should encourage the use of this treatment in cases falling into this category, regardless of the underlying disease, until there is no other evidence from randomized trials. Jakubíková et al [1] propose some interesting conclusions; however, essential data validated by large longitudinal studies are missing. Currently, cautious statements are advisable about predictive factors of outcome in MG during COVID‐19 infection.…”

“…Finally, Jakubíková et al [1] do not provide radiological details to better define the severity of COVID‐19 infection, especially for cases falling into categories scored as 5 and 6. Radiological findings, in our view, are crucial.…”

“…Finally, the authors [1] stated that long-term use of oral corticosteroids (CS) before COVID-19 increased the risk of severe pneumonia and therefore they suggest avoiding increased dosage during SARS-CoV-2 infection. This assumption is currently unproven and requires caution.…”

Corrigendum

“…In the article by Jakubíková et al [1], the grant number from the Ministry of Health of the Czech Republic was missed out under the Funding Information section on page 3418. The complete funding information should read:…”